Company research
Sagimet Biosciences Inc.
CIK 1400118Updated Nov 14, 2026
SecuritySGMT · NASDAQ · equity
Name history
3-V Biosciences, Inc. · through Feb 25, 2019
SGMT price & chart
Loading TradingView…
NASDAQ:SGMT on TradingView ↗About the company
Sagimet is a clinical-stage biopharmaceutical company advancing a portfolio of novel fatty acid synthase (FASN) inhibitors. FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can cause elevated sebum and inflammation. FASN is also implicated in other diseases, including MASH and certain FASN-dependent tumor types. Denifanstat, Sagimet’s lead drug candidate, is an oral, once-daily FASN inhibitor currently being evaluated in a U.S. Phase 3 registrational clinical trial for moderate to severe acne. For more information, visit www.sagimet.com.
In the news
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants ↗
Recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
424B3 filing
144 filing
Other Events
Items 8.01
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 128,401,000Source | 174,775,000Source | 263,430,000Source | 137,407,000Source | 189,020,000Source | 107,755,000Source | 146,172,000Source | 194,528,000Source | 116,482,000Source | 160,259,000Source | 96,719,000Source | 33,031,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 32,496,000Source | 77,014,000Source | 165,896,000Source | 42,327,000Source | 95,959,000Source | 36,626,000Source | 64,717,000Source | 176,777,000Source | 35,021,000Source | 75,840,000Source | 75,139,000Source | 158,000Source |
| Assets, CurrentUSD | 119,480,000Source | 157,190,000Source | 243,988,000Source | 127,196,000Source | 166,751,000Source | 107,716,000Source | 146,072,000Source | 194,491,000Source | 116,404,000Source | 152,774,000Source | 96,646,000Source | 32,792,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,787,000Source | 4,704,000Source | 3,860,000Source | 1,789,000Source | 378,000Source | 3,177,000Source | 1,503,000Source | 786,000Source | 3,280,000Source | 1,524,000Source | 1,749,000Source | 447,000Source |
| Operating Lease, Right-of-Use AssetUSD | 115,000Source | 114,000Source | 1,951,000Source | 152,000Source | 151,000Source | 39,000Source | 38,000Source | 37,000Source | 78,000Source | 77,000Source | 73,000Source | 212,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | 4,092,000Source | 7,275,000Source | — | 5,728,000Source | — | 7,180,000Source | 4,510,000Source | — | — | 5,654,000Source | 5,361,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | — | — | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | — | 1,000Source |
| Additional Paid in CapitalUSD | 455,916,000Source | 449,349,000Source | 627,178,000Source | 453,954,000Source | 447,803,000Source | 459,446,000Source | 452,355,000Source | 446,381,000Source | 457,607,000Source | 450,883,000Source | 340,777,000Source | 35,001,000Source |
| Retained Earnings (Accumulated Deficit)USD | -336,781,000Source | -279,110,000Source | -370,952,000Source | -323,873,000Source | -264,491,000Source | -356,999,000Source | -313,487,000Source | -256,373,000Source | -346,349,000Source | -295,311,000Source | -249,744,000Source | -221,868,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 117,000Source | 441,000Source | -77,000Source | 76,000Source | -23,000Source | 8,000Source | 121,000Source | 7,000Source | 120,000Source | 230,000Source | 30,000Source | -84,000Source |
| Stockholders' Equity Attributable to ParentUSD | 119,255,000Source | 170,683,000Source | 256,155,000Source | 130,160,000Source | 183,292,000Source | 102,458,000Source | 138,992,000Source | 190,018,000Source | 111,381,000Source | 155,805,000Source | 91,065,000Source | -186,950,000Source |
| Liabilities and EquityUSD | 128,401,000Source | 174,775,000Source | 263,430,000Source | 137,407,000Source | 189,020,000Source | 107,755,000Source | 146,172,000Source | 194,528,000Source | 116,482,000Source | 160,259,000Source | 96,719,000Source | 33,031,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,146,000Source | — | 5,419,000Source | 7,247,000Source | — | 5,297,000Source | — | — | 5,101,000Source | 4,454,000Source | 5,654,000Source | 5,279,000Source |
| Operating Lease, Liability, CurrentUSD | 115,000Source | 116,000Source | 84,000Source | 152,000Source | 153,000Source | 39,000Source | 39,000Source | 26,000Source | 78,000Source | 78,000Source | 65,000Source | 133,000Source |
| Accounts Payable, CurrentUSD | 4,243,000Source | 1,152,000Source | 1,131,000Source | 1,921,000Source | 1,994,000Source | 2,303,000Source | 3,223,000Source | 531,000Source | 1,309,000Source | 1,425,000Source | 186,000Source | 1,125,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 1,856,000Source | — | — | — | — | — | — | — | — | 78,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,788,000Source | 2,824,000Source | 4,204,000Source | 5,174,000Source | 3,581,000Source | 2,955,000Source | 3,918,000Source | 3,953,000Source | 3,714,000Source | 2,951,000Source | 5,403,000Source | 4,021,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 125,500,000Source | 170,000,000Source | 257,600,000Source | 135,500,000Source | 188,500,000Source | 104,500,000Source | 144,600,000Source | 193,700,000Source | 113,100,000Source | 158,700,000Source | 94,900,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 16,000Source | 16,000Source | 43,000Source | 45,000Source |
| Other Assets, Noncurrent | — | — | —Source | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,839,000Source | 1,472,000Source | 6,449,000Source | 5,288,000Source | 4,990,000Source | 1,880,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,611,000Source | -14,536,000Source | -45,650,000Source | -42,435,000Source | -23,766,000Source | -24,490,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 10,216,000Source | 3,413,000Source | 4,556,000Source | -61,683,000Source | 12,580,000Source | -32,010,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 275,000Source | 104,819,000Source | 86,167,000Source | -73,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 32,496,000Source | 77,014,000Source | 165,896,000Source | 42,327,000Source | 36,626,000Source | 64,717,000Source | 35,021,000Source | 75,840,000Source | 75,139,000Source | 158,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,688,000Source | 1,546,000Source | 3,691,000Source | 1,598,000Source | 1,839,000Source | 1,472,000Source | 6,449,000Source | 5,288,000Source | 4,990,000Source | 1,880,000Source |
| Amortization of Deferred ChargesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,400,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 125,500,000Source | 170,000,000Source | 257,600,000Source | 135,500,000Source | 104,500,000Source | 144,600,000Source | 113,100,000Source | 158,700,000Source | 94,900,000Source | — |
| General and Administrative ExpenseUSD | — | — | 4,604,000Source | 4,249,000Source | 4,283,000Source | 4,677,000Source | 4,718,000Source | 4,523,000Source | 17,835,000Source | 16,010,000Source | 12,963,000Source | 6,136,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,908,000Source | -14,619,000Source | -13,953,000Source | -10,386,000Source | -10,650,000Source | -18,176,000Source | -51,038,000Source | -45,567,000Source | -27,876,000Source | -30,499,000Source |
| Operating ExpensesUSD | — | — | 14,334,000Source | 16,902,000Source | 15,818,000Source | 11,925,000Source | 11,713,000Source | 19,865,000Source | 56,889,000Source | 54,454,000Source | 32,740,000Source | 31,055,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,426,000Source | 2,283,000Source | 1,865,000Source | 1,539,000Source | 1,063,000Source | 1,689,000Source | 5,851,000Source | 8,887,000Source | 2,864,000Source | 556,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 0Source | 1,045,000Source | 3,518,000Source | 85,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 105,750,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 275,000Source | 114,000Source | 6,000Source | 12,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | 2,000,000Source | — |
| Operating Income (Loss)USD | — | — | -14,334,000Source | -16,902,000Source | -15,818,000Source | -11,925,000Source | -11,713,000Source | -19,865,000Source | -56,889,000Source | -54,454,000Source | -30,740,000Source | -31,055,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,426,000Source | 2,283,000Source | 1,865,000Source | 1,539,000Source | 1,063,000Source | 1,689,000Source | 5,851,000Source | 8,887,000Source | 2,864,000Source | 556,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,908,000Source | -14,619,000Source | -13,953,000Source | -10,386,000Source | -10,650,000Source | -18,176,000Source | -51,038,000Source | -45,567,000Source | -27,876,000Source | -30,499,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.4Source | -0.45Source | -0.26Source | -0.32Source | -0.33Source | -0.56Source | -1.58Source | -1.45Source | -2.66Source | -165.2Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.4Source | -0.45Source | -0.26Source | -0.32Source | -0.33Source | -0.56Source | -1.58Source | -1.45Source | -2.66Source | -165.2Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 32,464,893Source | 32,143,336Source | 53,114,533Source | 32,195,366Source | 32,559,704Source | 32,195,345Source | 32,345,525Source | 31,350,725Source | 10,460,335Source | 184,619Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 32,464,893Source | 32,143,336Source | 53,114,533Source | 32,195,366Source | 32,559,704Source | 32,195,345Source | 32,345,525Source | 31,350,725Source | 10,460,335Source | 184,619Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,604,000Source | 4,249,000Source | 4,283,000Source | 4,677,000Source | 4,718,000Source | 4,523,000Source | 17,835,000Source | 16,010,000Source | 12,963,000Source | 6,136,000Source |
| Interest and Other IncomeUSD | — | — | 1,426,000Source | 2,283,000Source | 1,865,000Source | 1,539,000Source | 1,063,000Source | 1,689,000Source | 5,851,000Source | 8,887,000Source | 2,860,000Source | 553,000Source |
| Operating ExpensesUSD | — | — | 14,334,000Source | 16,902,000Source | 15,818,000Source | 11,925,000Source | 11,713,000Source | 19,865,000Source | 56,889,000Source | 54,454,000Source | 32,740,000Source | 31,055,000Source |
| Research and Development ExpenseUSD | — | — | 9,730,000Source | 12,653,000Source | 11,535,000Source | 7,248,000Source | 6,995,000Source | 15,342,000Source | 39,054,000Source | 38,444,000Source | 19,777,000Source | 24,919,000Source |
Filing attachments
d123481dex991.htm · 8-K · 2026-11-12
Exhibit 99.1 Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clin…
Read attachment ↗d123481dex992.htm · 8-K · 2026-11-12
Exhibit 99.2 Targeting Metabolic Dysfunction with Novel Therapeutics November 2026 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements…
Read attachment ↗d124492dex991.htm · 8-K · 2026-10-22
Targeting Metabolic Dysfunction with Novel Therapeutics October 2026 Exhibit 99.1 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements …
Read attachment ↗d136610dex41.htm · 8-K · 2026-10-01
Exhibit 4.1 The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. SAGIMET BIOSCIENCES INC. FORM OF PRE-FUNDED WARRANT TO …
Read attachment ↗d96035dex991.htm · 8-K · 2026-09-30
Exhibit 99.1 Targeting Metabolic Dysfunction with Novel Therapeutics September 2026 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statement…
Read attachment ↗d96035dex992.htm · 8-K · 2026-09-30
Exhibit 99.2 Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed progressive and sustained improvements across all efficacy endpoints in the OLE, including Investigator’s Global Asses…
Read attachment ↗